Details of the Drug

General Information of Drug (ID: DMQYUWG)

Drug Name

Toremifene

Synonyms

Acapodene; Estrimex; Farestone; Toremifeno; Toremifenum; Toremifene Base; Toremifeno [Spanish]; Toremifenum [Latin]; GTx 006; Acapodene (TN); FC-1157a; Fareston (TN); GTx-006; Toremifene (INN); Toremifene [INN:BAN]; Z-Toremifene; GTX-006 (Acapodene); Toremifene Citrate (1:1); {2-[4-(4-Chloro-1,2-diphenyl-but-1-enyl)-phenoxy]-ethyl}-dimethyl-amine; (Z)-2-(4-(4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine; 2-(p-[(Z)-4-chloro-1,2-diphenyl-1-butenyl]-phenoxy)-N,N-dimethyl-ethylamine citrate(1:1); 2-(para-((Z)-4-Chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine (IUPAC); 2-({4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenyl}oxy)-N,N-dimethylethanamine; 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Investigative	[2]
------------------------------------------------------------------------------------

Therapeutic Class

Anticancer Agents

Affected Organisms

Humans and other mammals

ATC Code

L02BA02: Toremifene

L02BA: Anti-estrogens

L02B: HORMONE ANTAGONISTS AND RELATED AGENTS

L02: ENDOCRINE THERAPY

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 1

Molecular Weight (mw)

406

Logarithm of the Partition Coefficient (xlogp)

7.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: 99% of drug becomes completely available to its intended biological destination(s) [4]
Elimination: 0.1% of drug is excreted from urine in the unchanged form [3]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.20253 micromolar/kg/day [5]
Water Solubility: The ability of drug to dissolve in water is measured as 0.38 mg/mL [3]

Chemical Identifiers

Formula: C26H28ClNO
IUPAC Name: 2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine
Canonical SMILES: CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\\C2=CC=CC=C2)/C3=CC=CC=C3
InChI: InChI=1S/C26H28ClNO/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21/h3-16H,17-20H2,1-2H3/b26-25-
InChIKey: XFCLJVABOIYOMF-QPLCGJKRSA-N

Cross-matching ID

PubChem CID: 3005573
ChEBI ID: CHEBI:9635
CAS Number: 89778-26-7
UNII: 7NFE54O27T
DrugBank ID: DB00539
TTD ID: D04VFJ
VARIDT ID: DR01170
INTEDE ID: DR1623
ACDINA ID: D00691

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Estrogen receptor (ESR)	TTZAYWL	ESR1_HUMAN	Modulator	[6]
COVID-19 non-structural protein 14 (nsp14)	TTC2DS7	R1AB_SARS2	Inhibitor	[2]
COVID-19 spike glycoprotein (S)	TTZ3COY	SPIKE_SARS2	Inhibitor	[2]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Cytochrome P450 1A1 (CYP1A1)	DE6OQ3W	CP1A1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Breast cancer

ICD Disease Classification

2C60-2C65

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
P-glycoprotein 1 (ABCB1)	DTP	P-GP	7.23E-01	-8.20E-02	-3.22E-01
Cytochrome P450 1A1 (CYP1A1)	DME	CYP1A1	5.01E-01	-1.01E-02	-6.05E-02
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.85E-01	2.24E-02	7.33E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Toremifene

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Toremifene and Eribulin.	Breast cancer [2C60-2C6Y]	[10]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Toremifene and Lapatinib.	Breast cancer [2C60-2C6Y]	[10]
Tucatinib	DMBESUA	Major	Decreased metabolism of Toremifene caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[11]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Toremifene and Bosutinib.	Breast cancer [2C60-2C6Y]	[10]
-----------

Coadministration of a Drug Treating the Disease Different from Toremifene (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Metreleptin	DM1NOEK	Moderate	Increased metabolism of Toremifene caused by Metreleptin mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[12]
Pioglitazone	DMKJ485	Moderate	Increased metabolism of Toremifene caused by Pioglitazone mediated induction of CYP450 enzyme.	Acute diabete complication [5A2Y]	[13]
Nateglinide	DMLK2QH	Moderate	Decreased metabolism of Toremifene caused by Nateglinide mediated inhibition of CYP450 enzyme.	Acute diabete complication [5A2Y]	[14]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Toremifene and Ivosidenib.	Acute myeloid leukaemia [2A60]	[10]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Toremifene and Midostaurin.	Acute myeloid leukaemia [2A60]	[10]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Toremifene and Idarubicin.	Acute myeloid leukaemia [2A60]	[10]
Daunorubicin	DMQUSBT	Major	Increased risk of prolong QT interval by the combination of Toremifene and Daunorubicin.	Acute myeloid leukaemia [2A60]	[10]
Arn-509	DMT81LZ	Major	Increased metabolism of Toremifene caused by Arn-509 mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[12]
Gilteritinib	DMTI0ZO	Major	Increased risk of prolong QT interval by the combination of Toremifene and Gilteritinib.	Acute myeloid leukaemia [2A60]	[10]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Toremifene and Oliceridine.	Acute pain [MG31]	[10]
Mitotane	DMU1GX0	Major	Increased metabolism of Toremifene caused by Mitotane mediated induction of CYP450 enzyme.	Adrenal cancer [2D11]	[12]
Galantamine	DMEO794	Moderate	Increased risk of ventricular arrhythmias by the combination of Toremifene and Galantamine.	Alzheimer disease [8A20]	[10]
Rivastigmine	DMG629M	Moderate	Increased risk of ventricular arrhythmias by the combination of Toremifene and Rivastigmine.	Alzheimer disease [8A20]	[10]
Donepezil	DMIYG7Z	Moderate	Increased risk of ventricular arrhythmias by the combination of Toremifene and Donepezil.	Alzheimer disease [8A20]	[10]
Metronidazole	DMTIVEN	Minor	Increased risk of prolong QT interval by the combination of Toremifene and Metronidazole.	Amoebiasis [1A36]	[15]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Toremifene and Bepridil.	Angina pectoris [BA40]	[10]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Toremifene and Dronedarone.	Angina pectoris [BA40]	[10]
Nifedipine	DMSVOZT	Moderate	Decreased metabolism of Toremifene caused by Nifedipine mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[11]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Toremifene and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[10]
Methylphenobarbital	DMDSWAG	Moderate	Increased metabolism of Toremifene caused by Methylphenobarbital mediated induction of CYP450 enzyme.	Anxiety disorder [6B00-6B0Z]	[15]
Hydroxyzine	DMF8Y74	Major	Increased risk of prolong QT interval by the combination of Toremifene and Hydroxyzine.	Anxiety disorder [6B00-6B0Z]	[10]
Cilostazol	DMZMSCT	Major	Increased risk of prolong QT interval by the combination of Toremifene and Cilostazol.	Arterial occlusive disease [BD40]	[10]
Voriconazole	DMAOL2S	Major	Decreased metabolism of Toremifene caused by Voriconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[11]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Toremifene and Posaconazole.	Aspergillosis [1F20]	[10]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Toremifene and Levalbuterol.	Asthma [CA23]	[16]
Terbutaline	DMD4381	Major	Increased risk of prolong QT interval by the combination of Toremifene and Terbutaline.	Asthma [CA23]	[17]
Zafirlukast	DMHNQOG	Moderate	Decreased metabolism of Toremifene caused by Zafirlukast mediated inhibition of CYP450 enzyme.	Asthma [CA23]	[11]
Pirbuterol	DMI5678	Moderate	Increased risk of prolong QT interval by the combination of Toremifene and Pirbuterol.	Asthma [CA23]	[17]
Salbutamol	DMN9CWF	Moderate	Increased risk of ventricular arrhythmias by the combination of Toremifene and Salbutamol.	Asthma [CA23]	[18]
Formoterol	DMSOURV	Moderate	Increased risk of ventricular arrhythmias by the combination of Toremifene and Formoterol.	Asthma [CA23]	[17]
Lisdexamfetamine	DM6W8V5	Major	Increased risk of prolong QT interval by the combination of Toremifene and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[10]
Desipramine	DMT2FDC	Major	Increased risk of prolong QT interval by the combination of Toremifene and Desipramine.	Attention deficit hyperactivity disorder [6A05]	[10]
Ofloxacin	DM0VQN3	Major	Increased risk of prolong QT interval by the combination of Toremifene and Ofloxacin.	Bacterial infection [1A00-1C4Z]	[10]
Oritavancin	DM28D05	Moderate	Increased metabolism of Toremifene caused by Oritavancin mediated induction of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[12]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Toremifene caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[19]
Clarithromycin	DM4M1SG	Major	Decreased metabolism of Toremifene caused by Clarithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[11]
Sulfamethoxazole	DMB08GE	Minor	Increased risk of prolong QT interval by the combination of Toremifene and Sulfamethoxazole.	Bacterial infection [1A00-1C4Z]	[10]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Toremifene and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[20]
Gemifloxacin	DMHT34O	Major	Increased risk of prolong QT interval by the combination of Toremifene and Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[10]
Norfloxacin	DMIZ6W2	Major	Increased risk of prolong QT interval by the combination of Toremifene and Norfloxacin.	Bacterial infection [1A00-1C4Z]	[10]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Toremifene caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[11]
Lomefloxacin	DMVRH9C	Major	Increased risk of prolong QT interval by the combination of Toremifene and Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[10]
Telithromycin	DMZ4P3A	Major	Decreased metabolism of Toremifene caused by Telithromycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[11]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Toremifene and Retigabine.	Behcet disease [4A62]	[10]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Toremifene caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[12]
Loperamide	DMOJZQ9	Moderate	Increased risk of prolong QT interval by the combination of Toremifene and Loperamide.	Bowel habit change [ME05]	[21]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Toremifene and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[10]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Toremifene and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Toremifene and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[16]
Salmeterol	DMIEU69	Moderate	Increased risk of ventricular arrhythmias by the combination of Toremifene and Salmeterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Indacaterol	DMQJHR7	Moderate	Increased risk of prolong QT interval by the combination of Toremifene and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Toremifene and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[17]
Phenylbutazone	DMAYL0T	Moderate	Increased metabolism of Toremifene caused by Phenylbutazone mediated induction of CYP450 enzyme.	Chronic pain [MG30]	[12]
Anisindione	DM2C48U	Moderate	Decreased metabolism of Toremifene caused by Anisindione mediated inhibition of CYP450 enzyme.	Coagulation defect [3B10]	[15]
Isoproterenol	DMK7MEY	Major	Increased risk of prolong QT interval by the combination of Toremifene and Isoproterenol.	Conduction disorder [BC63]	[17]
Halothane	DM80OZ5	Major	Increased risk of prolong QT interval by the combination of Toremifene and Halothane.	Corneal disease [9A76-9A78]	[10]
Propofol	DMB4OLE	Moderate	Increased risk of prolong QT interval by the combination of Toremifene and Propofol.	Corneal disease [9A76-9A78]	[22]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Toremifene and Sevoflurane.	Corneal disease [9A76-9A78]	[10]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Toremifene and Probucol.	Coronary atherosclerosis [BA80]	[10]
Clofazimine	DMEBOFW	Major	Increased risk of prolong QT interval by the combination of Toremifene and Clofazimine.	Crohn disease [DD70]	[10]
Mifepristone	DMGZQEF	Major	Increased risk of prolong QT interval by the combination of Toremifene and Mifepristone.	Cushing syndrome [5A70]	[10]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Toremifene and Pasireotide.	Cushing syndrome [5A70]	[10]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Toremifene and Osilodrostat.	Cushing syndrome [5A70]	[10]
Lumacaftor	DMCLWDJ	Major	Increased metabolism of Toremifene caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[12]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Toremifene caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[11]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Toremifene caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[11]
Aprepitant	DM053KT	Moderate	Decreased metabolism of Toremifene caused by Aprepitant mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[11]
Sertraline	DM0FB1J	Major	Increased risk of prolong QT interval by the combination of Toremifene and Sertraline.	Depression [6A70-6A7Z]	[10]
Trimipramine	DM1SC8M	Major	Increased risk of prolong QT interval by the combination of Toremifene and Trimipramine.	Depression [6A70-6A7Z]	[10]
Nortriptyline	DM4KDYJ	Major	Increased risk of prolong QT interval by the combination of Toremifene and Nortriptyline.	Depression [6A70-6A7Z]	[10]
Nefazodone	DM4ZS8M	Major	Decreased metabolism of Toremifene caused by Nefazodone mediated inhibition of CYP450 enzyme.	Depression [6A70-6A7Z]	[11]
Escitalopram	DMFK9HG	Major	Increased risk of prolong QT interval by the combination of Toremifene and Escitalopram.	Depression [6A70-6A7Z]	[10]
Clomipramine	DMINRKW	Major	Increased risk of prolong QT interval by the combination of Toremifene and Clomipramine.	Depression [6A70-6A7Z]	[10]
Trazodone	DMK1GBJ	Major	Increased risk of prolong QT interval by the combination of Toremifene and Trazodone.	Depression [6A70-6A7Z]	[10]
Amoxapine	DMKITQE	Major	Increased risk of prolong QT interval by the combination of Toremifene and Amoxapine.	Depression [6A70-6A7Z]	[10]
Doxepin	DMPI98T	Major	Increased risk of prolong QT interval by the combination of Toremifene and Doxepin.	Depression [6A70-6A7Z]	[10]
Maprotiline	DMPWB7T	Major	Increased risk of prolong QT interval by the combination of Toremifene and Maprotiline.	Depression [6A70-6A7Z]	[10]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Toremifene and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[10]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Toremifene and Deutetrabenazine.	Dystonic disorder [8A02]	[10]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Toremifene and Ingrezza.	Dystonic disorder [8A02]	[10]
Primidone	DM0WX6I	Major	Increased metabolism of Toremifene caused by Primidone mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Felbamate	DM1V5ZS	Moderate	Increased metabolism of Toremifene caused by Felbamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Oxcarbazepine	DM5PU6O	Moderate	Increased metabolism of Toremifene caused by Oxcarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Cenobamate	DM8KLU9	Moderate	Increased metabolism of Toremifene caused by Cenobamate mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Toremifene caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[11]
Fosphenytoin	DMOX3LB	Major	Increased metabolism of Toremifene caused by Fosphenytoin mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Rufinamide	DMWE60C	Moderate	Increased metabolism of Toremifene caused by Rufinamide mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Phenobarbital	DMXZOCG	Major	Increased metabolism of Toremifene caused by Phenobarbital mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Carbamazepine	DMZOLBI	Major	Increased metabolism of Toremifene caused by Carbamazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Eslicarbazepine	DMZREFQ	Moderate	Increased metabolism of Toremifene caused by Eslicarbazepine mediated induction of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[12]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Toremifene caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[12]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Toremifene and Solifenacin.	Functional bladder disorder [GC50]	[10]
Itraconazole	DMCR1MV	Major	Decreased metabolism of Toremifene caused by Itraconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[11]
Pentamidine	DMHZJCG	Major	Increased risk of prolong QT interval by the combination of Toremifene and Pentamidine.	Fungal infection [1F29-1F2F]	[10]
Miconazole	DMPMYE8	Moderate	Decreased metabolism of Toremifene caused by Miconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[11]
Ketoconazole	DMPZI3Q	Major	Decreased metabolism of Toremifene caused by Ketoconazole mediated inhibition of CYP450 enzyme.	Fungal infection [1F29-1F2F]	[11]
Cisapride	DMY7PED	Major	Increased risk of prolong QT interval by the combination of Toremifene and Cisapride.	Gastro-oesophageal reflux disease [DA22]	[10]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Toremifene and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[10]
Sulfinpyrazone	DMEV954	Moderate	Increased metabolism of Toremifene caused by Sulfinpyrazone mediated induction of CYP450 enzyme.	Gout [FA25]	[12]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Toremifene caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[11]
Telaprevir	DMMRV29	Major	Decreased metabolism of Toremifene caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[11]
Isoniazid	DM5JVS3	Moderate	Decreased metabolism of Toremifene caused by Isoniazid mediated inhibition of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[11]
Rifampin	DMA8J1G	Major	Increased metabolism of Toremifene caused by Rifampin mediated induction of CYP450 enzyme.	HIV-infected patients with tuberculosis [1B10-1B14]	[12]
Delavirdine	DM3NF5G	Major	Decreased metabolism of Toremifene caused by Delavirdine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Toremifene caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Toremifene and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Toremifene caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Efavirenz	DMC0GSJ	Major	Increased risk of prolong QT interval by the combination of Toremifene and Efavirenz.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Toremifene and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Toremifene caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[12]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Toremifene and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[10]
Amprenavir	DMLMXE0	Major	Decreased metabolism of Toremifene caused by Amprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Toremifene caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Atazanavir	DMSYRBX	Major	Decreased metabolism of Toremifene caused by Atazanavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[11]
Fluvastatin	DM4MDJY	Moderate	Decreased metabolism of Toremifene caused by Fluvastatin mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[15]
Verapamil	DMA7PEW	Moderate	Decreased metabolism of Toremifene caused by Verapamil mediated inhibition of CYP450 enzyme.	Hypertension [BA00-BA04]	[11]
Conivaptan	DM1V329	Major	Decreased metabolism of Toremifene caused by Conivaptan mediated inhibition of CYP450 enzyme.	Hypo-osmolality/hyponatraemia [5C72]	[11]
Lesinurad	DMUR64T	Moderate	Decreased metabolism of Toremifene caused by Lesinurad mediated inhibition of CYP450 enzyme.	Inborn purine/pyrimidine/nucleotide metabolism error [5C55]	[24]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Toremifene caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[11]
Amobarbital	DM0GQ8N	Moderate	Increased metabolism of Toremifene caused by Amobarbital mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[12]
Polyethylene glycol	DM4I1JP	Major	Increased risk of ventricular arrhythmias by the combination of Toremifene and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[25]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Toremifene and Phenolphthalein.	Irritable bowel syndrome [DD91]	[10]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Toremifene and Crizotinib.	Lung cancer [2C25]	[10]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Toremifene caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[12]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Toremifene and Ceritinib.	Lung cancer [2C25]	[10]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Toremifene caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[12]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Toremifene and Osimertinib.	Lung cancer [2C25]	[10]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Toremifene and Selpercatinib.	Lung cancer [2C25]	[10]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Toremifene and Lumefantrine.	Malaria [1F40-1F45]	[15]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Toremifene and Halofantrine.	Malaria [1F40-1F45]	[26]
Chloroquine	DMSI5CB	Major	Increased risk of prolong QT interval by the combination of Toremifene and Chloroquine.	Malaria [1F40-1F45]	[10]
Hydroxychloroquine	DMSIVND	Major	Increased risk of prolong QT interval by the combination of Toremifene and Hydroxychloroquine.	Malaria [1F40-1F45]	[10]
Primaquine	DMWQ16I	Major	Increased risk of prolong QT interval by the combination of Toremifene and Primaquine.	Malaria [1F40-1F45]	[10]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Toremifene and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[10]
Idelalisib	DM602WT	Major	Decreased metabolism of Toremifene caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[11]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Toremifene caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[11]
Arsenic trioxide	DM61TA4	Major	Increased risk of ventricular arrhythmias by the combination of Toremifene and Arsenic trioxide.	Mature B-cell lymphoma [2A85]	[27]
Vemurafenib	DM62UG5	Major	Increased risk of prolong QT interval by the combination of Toremifene and Vemurafenib.	Melanoma [2C30]	[10]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Toremifene and LGX818.	Melanoma [2C30]	[10]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Toremifene caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[28]
Danazol	DML8KTN	Moderate	Decreased metabolism of Toremifene caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[11]
Exjade	DMHPRWG	Moderate	Increased metabolism of Toremifene caused by Exjade mediated induction of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[12]
Carfilzomib	DM48K0X	Major	Additive thrombogenic effects by the combination of Toremifene and Carfilzomib.	Multiple myeloma [2A83]	[15]
Panobinostat	DM58WKG	Major	Increased risk of prolong QT interval by the combination of Toremifene and Panobinostat.	Multiple myeloma [2A83]	[10]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Toremifene and Siponimod.	Multiple sclerosis [8A40]	[15]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Toremifene and Fingolimod.	Multiple sclerosis [8A40]	[10]
Ozanimod	DMT6AM2	Major	Increased risk of prolong QT interval by the combination of Toremifene and Ozanimod.	Multiple sclerosis [8A40]	[10]
Rifabutin	DM1YBHK	Major	Increased metabolism of Toremifene caused by Rifabutin mediated induction of CYP450 enzyme.	Mycobacterium infection [1B10-1B21]	[12]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Toremifene and Romidepsin.	Mycosis fungoides [2B01]	[10]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Toremifene caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[11]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Toremifene and Nilotinib.	Myeloproliferative neoplasm [2A20]	[10]
Imatinib	DM7RJXL	Moderate	Decreased metabolism of Toremifene caused by Imatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[11]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Toremifene and Dasatinib.	Myeloproliferative neoplasm [2A20]	[10]
Modafinil	DMYILBE	Moderate	Increased metabolism of Toremifene caused by Modafinil mediated induction of CYP450 enzyme.	Narcolepsy [7A20]	[12]
Promethazine	DM6I5GR	Major	Increased risk of prolong QT interval by the combination of Toremifene and Promethazine.	Nausea/vomiting [MD90]	[10]
Granisetron	DMIUW25	Major	Increased risk of prolong QT interval by the combination of Toremifene and Granisetron.	Nausea/vomiting [MD90]	[10]
Dolasetron	DMMG26Z	Major	Increased risk of prolong QT interval by the combination of Toremifene and Dolasetron.	Nausea/vomiting [MD90]	[10]
Ondansetron	DMOTQ1I	Major	Increased risk of prolong QT interval by the combination of Toremifene and Ondansetron.	Nausea/vomiting [MD90]	[10]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Toremifene and Entrectinib.	Non-small cell lung cancer [2C25]	[10]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Toremifene and Levomethadyl Acetate.	Opioid use disorder [6C43]	[28]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Toremifene and Lofexidine.	Opioid use disorder [6C43]	[10]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Toremifene and Rucaparib.	Ovarian cancer [2C73]	[10]
Dextropropoxyphene	DM23HCX	Major	Increased risk of prolong QT interval by the combination of Toremifene and Dextropropoxyphene.	Pain [MG30-MG3Z]	[10]
Buprenorphine	DMPRI8G	Major	Increased risk of prolong QT interval by the combination of Toremifene and Buprenorphine.	Pain [MG30-MG3Z]	[10]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Toremifene and Triclabendazole.	Parasitic worm infestation [1F90]	[10]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Toremifene and Pimavanserin.	Parkinsonism [8A00]	[10]
Apomorphine	DMX38HQ	Major	Increased risk of prolong QT interval by the combination of Toremifene and Apomorphine.	Parkinsonism [8A00]	[10]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Toremifene caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[29]
Famotidine	DMRL3AB	Moderate	Increased risk of prolong QT interval by the combination of Toremifene and Famotidine.	Peptic ulcer [DA61]	[15]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Toremifene and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[30]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Toremifene and Lefamulin.	Pneumonia [CA40]	[31]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Toremifene caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[11]
Ritodrine	DM4V6RL	Major	Increased risk of prolong QT interval by the combination of Toremifene and Ritodrine.	Preterm labour/delivery [JB00]	[17]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Toremifene and Degarelix.	Prostate cancer [2C82]	[10]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Toremifene and ABIRATERONE.	Prostate cancer [2C82]	[10]
Nilutamide	DMFN07X	Major	Increased risk of prolong QT interval by the combination of Toremifene and Nilutamide.	Prostate cancer [2C82]	[10]
Enzalutamide	DMGL19D	Major	Increased metabolism of Toremifene caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[12]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Toremifene and Relugolix.	Prostate cancer [2C82]	[10]
Bicalutamide	DMZMSPF	Major	Increased risk of prolong QT interval by the combination of Toremifene and Bicalutamide.	Prostate cancer [2C82]	[10]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Toremifene and Levomepromazine.	Psychotic disorder [6A20-6A25]	[10]
Fluphenazine	DMIT8LX	Major	Increased risk of prolong QT interval by the combination of Toremifene and Fluphenazine.	Psychotic disorder [6A20-6A25]	[10]
Bosentan	DMIOGBU	Moderate	Increased metabolism of Toremifene caused by Bosentan mediated induction of CYP450 enzyme.	Pulmonary hypertension [BB01]	[12]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Toremifene and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[32]
Gatifloxacin	DMSL679	Major	Increased risk of prolong QT interval by the combination of Toremifene and Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[10]
Dexamethasone	DMMWZET	Major	Increased metabolism of Toremifene caused by Dexamethasone mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[12]
Nafcillin	DMN9RPO	Moderate	Increased metabolism of Toremifene caused by Nafcillin mediated induction of CYP450 enzyme.	Rheumatoid arthritis [FA20]	[12]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Toremifene and Quetiapine.	Schizophrenia [6A20]	[10]
Mesoridazine	DM2ZGAN	Major	Increased risk of prolong QT interval by the combination of Toremifene and Mesoridazine.	Schizophrenia [6A20]	[10]
Thioridazine	DM35M8J	Major	Increased risk of prolong QT interval by the combination of Toremifene and Thioridazine.	Schizophrenia [6A20]	[10]
Aripiprazole	DM3NUMH	Moderate	Increased risk of prolong QT interval by the combination of Toremifene and Aripiprazole.	Schizophrenia [6A20]	[15]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Toremifene and Iloperidone.	Schizophrenia [6A20]	[10]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Toremifene and Paliperidone.	Schizophrenia [6A20]	[10]
Perphenazine	DMA4MRX	Major	Increased risk of prolong QT interval by the combination of Toremifene and Perphenazine.	Schizophrenia [6A20]	[10]
Trifluoperazine	DMKBYWI	Major	Increased risk of prolong QT interval by the combination of Toremifene and Trifluoperazine.	Schizophrenia [6A20]	[10]
Risperidone	DMN6DXL	Major	Increased risk of prolong QT interval by the combination of Toremifene and Risperidone.	Schizophrenia [6A20]	[10]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Toremifene and Amisulpride.	Schizophrenia [6A20]	[10]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Toremifene and Asenapine.	Schizophrenia [6A20]	[10]
Pimozide	DMW83TP	Major	Increased risk of prolong QT interval by the combination of Toremifene and Pimozide.	Schizophrenia [6A20]	[28]
Vardenafil	DMTBGW8	Major	Increased risk of prolong QT interval by the combination of Toremifene and Vardenafil.	Sexual dysfunction [HA00-HA01]	[10]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Toremifene caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[11]
Telotristat ethyl	DMDIYFZ	Moderate	Increased metabolism of Toremifene caused by Telotristat ethyl mediated induction of CYP450 enzyme.	Small intestine developmental anomaly [DA90]	[15]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Toremifene caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[11]
Armodafinil	DMGB035	Moderate	Increased metabolism of Toremifene caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[12]
LEE011	DMMX75K	Major	Decreased metabolism of Toremifene caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[10]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Toremifene and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[33]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Toremifene and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[10]
Doxorubicin	DMVP5YE	Major	Increased risk of prolong QT interval by the combination of Toremifene and Doxorubicin.	Solid tumour/cancer [2A00-2F9Z]	[10]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Toremifene and Pitolisant.	Somnolence [MG42]	[10]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Toremifene and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[10]
Warfarin	DMJYCVW	Moderate	Decreased metabolism of Toremifene caused by Warfarin mediated inhibition of CYP450 enzyme.	Supraventricular tachyarrhythmia [BC81]	[15]
Adenosine	DMM2NSK	Major	Increased risk of ventricular arrhythmias by the combination of Toremifene and Adenosine.	Supraventricular tachyarrhythmia [BC81]	[34]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Toremifene caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[35]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Toremifene and Lenvatinib.	Thyroid cancer [2D10]	[10]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Toremifene and Cabozantinib.	Thyroid cancer [2D10]	[10]
Papaverine	DMCA9QP	Major	Increased risk of prolong QT interval by the combination of Toremifene and Papaverine.	Tonus and reflex abnormality [MB47]	[36]
Tizanidine	DMR2IQ4	Major	Increased risk of prolong QT interval by the combination of Toremifene and Tizanidine.	Tonus and reflex abnormality [MB47]	[10]
Sirolimus	DMGW1ID	Moderate	Increased plasma concentrations of Toremifene and Sirolimus due to competitive inhibition of the same metabolic pathway.	Transplant rejection [NE84]	[32]
Tacrolimus	DMZ7XNQ	Major	Increased risk of prolong QT interval by the combination of Toremifene and Tacrolimus.	Transplant rejection [NE84]	[10]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Toremifene caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[12]
Astemizole	DM2HN6Q	Major	Increased risk of prolong QT interval by the combination of Toremifene and Astemizole.	Vasomotor/allergic rhinitis [CA08]	[10]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Toremifene and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[10]
Procainamide	DMNMXR8	Major	Increased risk of prolong QT interval by the combination of Toremifene and Procainamide.	Ventricular tachyarrhythmia [BC71]	[10]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Toremifene and Propafenone.	Ventricular tachyarrhythmia [BC71]	[10]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Toremifene and Flecainide.	Ventricular tachyarrhythmia [BC71]	[10]
Amiodarone	DMUTEX3	Major	Increased risk of prolong QT interval by the combination of Toremifene and Amiodarone.	Ventricular tachyarrhythmia [BC71]	[10]
-----------


⏷ Show the Full List of 225 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Toremifene 60 mg tablet	60 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4325).
2	Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2. June 5, 2020.
3	BDDCS applied to over 900 drugs
4	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	Effect of selective estrogen receptor modulators on cell proliferation and estrogen receptor activities in normal human prostate stromal and epithe... Prostate Cancer Prostatic Dis. 2009;12(4):375-81.
7	Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
8	Drug interaction potential of toremifene and N-desmethyltoremifene with multiple cytochrome P450 isoforms. Xenobiotica. 2011 Oct;41(10):851-62.
9	Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes. Biochem Pharmacol. 1994 May 18;47(10):1883-95.
10	Canadian Pharmacists Association.
11	Product Information. Fareston (toremifene). Schering Laboratories, Kenilworth, NJ.
12	Berthou F, Dreano Y, Belloc C, Kangas L, Gautier JC, Beaune P "Involvement of cytochrome P450 3A enzyme family in the major metabolic pathways of toremifene in human liver microsomes." Biochem Pharmacol 47 (1994): 1883-95. [PMID: 8204106]
13	Product Information. Actos (pioglitazone) Takeda Pharmaceuticals America, Lincolnshire, IL.
14	Product Information. Starlix (nateglinide) Novartis Pharmaceuticals, East Hanover, NJ.
15	Cerner Multum, Inc. "Australian Product Information.".
16	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
17	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
18	Gelmont DM, Balmes JR, Yee A "Hypokalemia induced by inhaled bronchodilators." Chest 94 (1988): 763-6. [PMID: 3168573]
19	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
20	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
21	Eggleston W, Clark KH, Marraffa JM "Loperamide abuse associated with cardiac dysrhythmia and death." Ann Emerg Med 69 (2017): 83-6. [PMID: 27140747]
22	Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
23	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
24	Product Information. Zurampic (lesinurad). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
25	Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
26	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
27	Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
28	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
30	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
31	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
32	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
33	Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
34	Celiker A, Tokel K, Cil E, Ozkutlu S, Ozme S "Adenosine induced torsades de pointes in a child with congenital long QT syndrome." Pacing Clin Electrophysiol 17 (1994): 1814-7. [PMID: 7838793]
35	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
36	Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]